Newsletter

www.DailyPennyStocks.com does its best to bring you accurate information but errors may and sometimes do occur. Always do your own research before trading. DailyPennyStocks.com is not a licensed financial advisor.  This is a paid advertisement, not a solicitation or recommendation to buy or sell securities.

The New "Friends in High Places" Super Story Stock is AXXE - Axxess Pharma 

About Axxess Pharma Inc.:

Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain to optimal health management through improved nutritional supplements.

For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.

AXXE a pharmaceutical company, engages in the marketing and distribution of various pharmaceutical products and diagnostic medical devices in Canada and internationally.

AXXE distributes dermatological, therapeutic nutritional, pain management, and diagnostic products.

AXXE’s principal product line includes Britical, Gravergol, Lactrase, Somnol, Triferexx, Urasal, Axspaz, Vivol, Hydraxx, Kemsol, Soropon, Amersol, Bactalase, Monurol, and Zynol, as well as skin care products.

AXXE distributes its products through physicians, hospitals, government and defense institutions, and pharmacies. The company was founded in 1997 and is headquartered in Markham, Canada.

Pain Management Now Worth Billions ($60 Billion Next Year)

The highly fragmented pain-management market poses an opportunity for new classes of drugs targeting neuropathic pain as well as for generics as standard therapies come off patent. Because current therapies are often less than effective or have undesirable side effects, there also are emerging opportunities using genomics to match patients to pain medications.

Pain management today is dominated by Pfizer, Eli Lilly, Purdue Pharma, Endo Pharmaceuticals, Novartis, Johnson & Johnson, and Grünenthal. “Among these, Purdue Pharma, Endo, and Grünenthal specialize in pain,” points out Karen Holmes, senior market analyst and author of the recent Espicom Business Intelligence report, Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development.

“Pfizer is by far the biggest player, consolidating its position with the acquisition of King Pharmaceuticals and Icagen. Including line extensions, Pfizer has at least 10 compounds in clinical development for pain indications.”

Whether those leaders will manage to maintain their positions depends upon how they manage their patent expirations as well as new drug development. “You have to be paranoid about the competition. The science isn’t stopping,” says John Steuart, managing partner, Claremont Creek Ventures. “Thousands of biotechs and tens of thousands of academic labs are working to develop new therapies all the time.” Pain management, he admits, is a mature market, so new therapies must be proven more efficacious or less toxic than existing medications.

Booming Market

Market projections vary, but Espicom estimated the global pain-management market at $46.4 BLN at the close of 2011. The U.S. market accounts for 48% of that. Another market analyst, Global Industry Analysts (GIA), one year ago predicted the global pain-management market would reach $60 BLN by 2015.

That predicted growth is based upon an aging global population, increasing number of surgeries, lifestyle changes, and a rising incidence of cancer. Some 1.5 BLN of the world’s 7 BLN people—21%—currently suffer from pain. That includes approximately 30% of all cancer patients and 60% of late-stage cancer patients.

The largest markets for pain-management medications currently are the U.S. and Europe. As with many pharmaceuticals, however, the fastest-growing markets are expected to be in Asia and Latin America, according to the GIA analysis, Pain Management: A Global Strategic Business Report. It anticipates a 9% compounded annual growth rate for pain-management therapies in Latin America between 2007 and 2015.

The pain management industry is an EXTREMELY powerful backdrop for a microcap growth story, and AXXE is telling a story that is sure to electrify investors...and potentially create VERY profitable "spikes" for traders to capitalize on.

http://finance.yahoo.com/q/h?s=AXXE+Headlines

The overall recent news story is really exciting.  I strongly suspect this is a story traders are going to respond to in a major way.  But I believe THIS WEEK'S press release in particular sets AXXE up for a quite possibly very dramatic increase in share price.

Take a look:

http://finance.yahoo.com/news/axxess-pharmas-aggressive-online-marketing-120000892.html

AXXE has literally just announced they anticipate that within 45 days they will generate an additional $1.5 MILLION in monthly gross sales!

With this big declaration just being put out, it looks like our timing on AXXE may be truly perfect.

You can read it here in its entirety in italics below:

TORONTO, ON--(Marketwired - Mar 17, 2014) - Axxess Pharma Inc. (PINKSHEETS: AXXE) a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have launched two additional websites http://buytapoutme.com and http://www.tapoutmusclerecovery.com.  The new websites are designed to aggressively market their new supplements line, TapouT Extreme Muscle Growth and TapouT Muscle Recovery. 

Management projects the new websites and product line will generate an additional $1.5 million in gross monthly sales for AllStar Health Brands. Sales are anticipated to flow into AllStar Health Brands within 45 days. Sales will be generated through a continued aggressive targeting of advertising on over 250,000 US websites. Some of these targeted websites include ESPN.com and NCAA.com. 

Dr. Daniel Bagi, President of Axxess Pharma and its subsidiary AllStar Health Brands stated: "We are proud to announce the launch of our new supplements line TapouT Extreme Muscle Growth and TapouT Muscle Recovery. This new supplement line will be sold through our recently launched websites." Dr. Bagi further stated, "This culminates many months of hard work in the development of two new products with what we consider the best formulas on the market. We expect this new URL-driven sales channel to grow very quickly in this high-demand market segment."

I'll break down the incredibly exciting AXXE/TapouT story in a nutshell for you right here, so you can see how this story is a one in a million situation I had to put in front of you today.

AXXE has a Worldwide Exclusive Agreement with TapouT.

TapouT is a World Leading Athletic Lifestyle Brand, with revenue of $350 million.

TapouT is owned by "Authentic Brands Group."  Authentic Brands Group is a MAJOR Company! 

Wikipedia states "ABG owns such popular consumer brands as Juicy Couture, Elvis Presley, Muhammad Ali, Marilyn Monroe, Prince Tennis, TapouT, Hickey Freeman, Judith Leiber and several others. Its brands are available in such stores as Kohl's, Kmart, Sears, Macy's, Bergdorf Goodman, Neiman Marcus, Bloomingdales, JC Penney and Walmart."

You wouldn't think the man who runs a Mega-Corporation like ABG would have anything to do with a tiny OTC Company.  Especially a super tiny one, like AXXE with a total market valuation of under $15 million.  The truth is the OTC market is plagued with frauds, plenty of Wolves of Wall Street, and just a general negative image...which is mostly well-deserved.  You could probably count on one hand the number of times a guy who runs an enormously powerful Corporate Empire goes on the record to praise a microcap company's product, as well as praising his partnership with them.

Yet this nearly unheard of  event happened for AXXE!

Nick Woodhouse, President for TapouT/Authentic Brands Group stated, "We are very excited about this partnership with Axxess Pharma, Inc. We feel that Axxess incredible pain relief formulas are going to be well received by TapouT customers across North America. As the TapouT brand continues to grow, Axxess will have an opportunity to grow with us."

Nick Woodhouse is the 2nd person named on the Wikipedia entry about Authentic Brands Group, only behind the Founder and CEO himself!  The guy who is the #2 head honcho at the Company who OWNS TapouT, is making positive comments, "ON THE RECORD"...about AXXE!

That's as strong a testament to the credibility of this Company as I've ever seen for any OTC company that gets promoted in newsletters.

You can look up the Wikipedia entry here: http://en.wikipedia.org/wiki/Authentic_Brands_Group

That makes me feel as "safe" as can be when it comes to trading AXXE.  But unfortunately, trusting that feeling would be a big mistake.  No matter how good or respectable, or even "undervalued" a company may appear to be...it has just as big a chance of crashing after you buy it as the most horrible sounding crap company you've  ever seen a newsletter talk about before.  AXXE can be a volatile and unpredictable little fellow, I love its profit potential but you've ALWAYS got to watch AXXE like a hawk and play it safe. ANY alert can go red, so use caution and trade safely. You may want to consider booking profits sooner rather than later, and possibly consider using a tight stop (mental works, if you can't enter one electronically) to make sure no trade goes too far against you.  Discuss these strategies with your local licensed professional. 

*** Be sure to trade with caution and to verify all information for yourself before trading.  Do your own research and consult with a licensed professional before trading any alert.  You may easily lose your entire investment.  In my personal opinion, the vast majority of companies alerted in this newsletter are too risky for traditional investment, and are discussed here purely from a short-term/daytrading perspective.  All traders should have substantial experience before engaging in the exceptionally risky process that is trading small, micro and nano-cap equities. ***

Now AXXE and all their TapouT branded products is about to launch an ultra-aggressive internet marketing campaigns and ram their merchandise down consumer's throats all over MAJOR players websites.  For the first time ever, consumers will start to see AXXE's TapouT products on ESPN.com, NCAA.com (college basketball), and a total of approx 250,000 websites as part of a MASS-SCALE Advertising Blitz.

And yet...AXXE is EXTREMELY cheap at just .29!

The increase of $1.5 million in monthly revenue would be an obvious catalyst for this super small and cheap company to blast off to a MUCH higher share price.

This "ad blitz" announcement is JUST hitting the Street and the reaction is at the very beginning phase, the timing is critical and this looks like a majorly hot setup.

With powerful friends like the President of Authentic Brands Group pushing for AXXE's success...the buzz could reach a fever pitch and turn AXXE into the most talked about ticker on the OTC.

All eyes on AXXE for a potential breakout!

DPS - Darth Trader

www.dailypennystocks.com

Don’t ever invest based on the info or statements of this newsletter.  Do your own research and consult with a licensed professional before investing, only invest what you are prepared to lose. Any statements and opinions given are amateur and biased and should be treated as such. Past performance does not indicate future performance in any way. The performance of all alerts uncompensated and compensated in no way predict the performance of current and/or upcoming alerts. Check the latest SEC filings before investing, and research other information on the risks of investing in microcap companies at www.sec.gov

 

READ IMPORTANT DISCLAIMER

Disclaimer – This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Focus Media.  Any reference to “we” or “our” refers to Focus Media.  Our business model is to be financially compensated to market and promote small public companies.  By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore unqualified to give investment recommendations. Always do your own research and consult with an licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
 
 
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.
 
 

We have been compensated twenty five thousand dollars cash via bank wire by a third party, Ramos and Ramos, to conduct the current investor relations advertising and marketing campaign for AXXE. We have also been compensated fifty thousand dollars cash via bank wire for a previous AXXE advertising campaign by a different third party, Ramm Venture Development, which is no longer active but should still be considered as a cause of bias. In total, we have been compensated seventy five thousand dollars for AXXE promotional marketing.  Focus Media’s business model is to receive financial compensation to promote public companies.  This compensation is a major conflict of interest in our ability to be unbiased regarding AXXE. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.


We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Focus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at www.dailypennystocks.com/disclaimer